
zzso a zzso small zzso has zzso activity in zzso zzso The drug zzso zzso through zzso of zzso oxygen zzso The purpose of this trial was to define the zzso dose zzso zzso zzso and zzso of zzso in patients with advanced zzso 

zzso patients with zzso cancer received intravenous zzso over 30 to 45 minutes for 5 consecutive days (one course) every other week zzso 1 through 5 and 15 through zzso zzso zzso were initially escalated using an accelerated trial design and then a modified zzso zzso Plasma zzso levels and six different zzso were measured by zzso liquid zzso zzso 

There were 13 dose levels zzso from 20 zzso to 1,000 zzso The zzso recommended for phase II studies was 875 zzso for 5 days every 2 weeks zzso zzso 9 zzso The two zzso zzso at 1,000 zzso involved grade 3 abdominal pain and fatigue and grade 4 zzso which occurred in one patient zzso Other common zzso included zzso and vomiting zzso and zzso zzso both were managed well with zzso zzso One partial response was obtained in a heavily zzso patient with zzso zzso zzso studies showed zzso zzso with a zzso mean zzso Plasma zzso studies showed a zzso and area under the zzso decrease in zzso levels 8 hours after dosing at 750 zzso 

The phase II recommended dose of zzso is 875 zzso for 5 days every other zzso A decrease in plasma zzso did correlate with zzso zzso 

